Verona Pharma PLC ADR

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. Show More...

  • Website https://www.veronapharma.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 81.20 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share GBP -3.2 -2.84 -3.28 -2.96 -1.28 -2.96 -1.2 -1.87 -1.51 -2.42 -2.74
    Dividends GBP
    Payout Ratio % *
    Shares Mil 1.0 1.0 1.0 1.0 2.0 3.0 4.0 11.0 13.0 13.0 13.0
    Book Value Per Share * USD 8.72 6.28 4.01 2.39
    Free Cash Flow Per Share * USD -2.65 -1.76 -2.97
    Return on Assets % -44.93 -43.74 -71.82 -94.2 -35.17 -72.26 -18.75 -30.22 -24.3 -53.5 -71.46
    Financial Leverage (Average) 1.06 1.04 1.08 1.24 1.04 1.32 1.34 1.12 1.18 1.33 1.39
    Return on Equity % -47.72 -45.85 -75.65 -108.09 -37.6 -81.54 -25.06 -35.85 -27.87 -65.99 -86.03
    Return on Invested Capital % -47.87 -45.95 -76.25 -108.19 -37.9 -81.95 -25.42 -36.34 -28.86 -65.88 -84.52
    Interest Coverage -783.12 -709.18
    Current Ratio 10.06 16.78 5.86 1.74 21.47 3.07 4.03 10.13 7.01 4.26 3.91
    Quick Ratio 9.86 16.49 5.84 1.74 21.47 3.07 3.79 9.42 6.44 3.35 2.83
    Debt/Equity 0.010 0.03